Does medicalization of life imperil health? Expanding indications for diagnosis and treatment of chronic "Disease"

Journal of Managed Care Pharmacy

Volumn 17, Issue 6, 2011, Pages 469-480

  Fairman, Kathleen A ^a   Curtiss, Frederic R ^a  

^a Academy of Managed Care Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METHYLPHENIDATE; MORPHINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; PRESCRIPTION DRUG;

ANALGESIA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DATA ANALYSIS; DRUG UTILIZATION; DYSLIPIDEMIA; EDITORIAL; GENERALIZED ANXIETY DISORDER; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH SURVEY; HUMAN; MEDICAL RECORD; MENTAL DISEASE; PAIN; PSYCHOSOCIAL DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); CHRONIC DISEASE; METHODOLOGY; PATHOPHYSIOLOGY; PRIMARY PREVENTION; UNITED STATES;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; MENTAL DISORDERS; PAIN; PRESCRIPTION DRUGS; PRIMARY PREVENTION; UNITED STATES;

EID: 84855742357     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.6.469     Document Type: Editorial

References (74)

1. Shea SE, Gordon K, Hawkins A, Kawchuk J, Smith D. Pathology in the Hundred Acre Wood: a neurodevelopmental perspective on A.A. Milne. CMAJ. 2000;163(12):1557-59. Available at: http://www.cmaj.ca/cgi/reprint/163/12/1557. Accessed June 16, 2011.
2. Beck M. Fictional stars, real problems. Wall Street J. June 8, 2010:D1.
3. Moynihan R. A new deal on disease definition. BMJ. 2011;342:d2548. doi: 10.1136/bmj.d2548.
4. Kaplan RM, Ong M. Rationale and public health implications of changing CHD risk factor definitions. Annu Rev Public Health. 2007;28:321-44.
5. National Institutes of Health, National Heart, Lung, and Blood Institute. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication 03-5233. December 2003. Available at: http://www.nhlbi.nih. gov/guidelines/hypertension/express.pdf. Accessed June 22, 2011.
6. National Institutes of Health, National Heart, Lung, and Blood Institute. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication 98-4080. November 1997. Available at: http://www.nhlbi.nih.gov/guidelines/archives/jnc6/jnc6_archive.pdf. Accessed June 22, 2011.
7. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25(3):305-13. Available at: http://hyper.ahajournals.org/cgi/content/full/25/3/305. Accessed June 22, 2011.
8. National Institutes of Health, National Heart, Lung, and Blood Institute, National Cholesterol Education Program. ATP III guidelines-at-a-glance: quick desk reference. May 2001. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf. Accessed June 22, 2011.
9. Grundy SM, Cleeman JI, Merz CN, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-39. Available at: http://circ.ahajournals.org/cgi/content/full/110/2/227. Accessed July 14, 2011.
10. Genuth S, Alberti KG, Bennett P, et al Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160-67. Available at: http://care.diabetesjournals.org/content/26/11/3160.long. Accessed July 15, 2011.
11. No author listed. Attenuated psychosis syndrome: William Carpenter, MD. The Carlat Psychiatry Report. June 2011;4-5.
12. Cornblatt BA, Correll CU. A new diagnostic entity in DSM-5? September 3, 2010. Available at: http://www.medscape.com/viewarticle/727682_print. Accessed July 7, 2011.
13. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904878/?tool=pubmed. Accessed July 7, 2011.
14. Davidson MB, Landsman PB, Alexander CM. Lowering the criterion for impaired fasting glucose will not provide clinical benefit. Diabetes Care. 2003;26(12):3329-30. Available at: http://care.diabetesjournals.org/content/26/12/3329.long. Accessed July 15, 2011.
15. Teitelbaum F, Martinez R, Parker A, et al. Express Scripts Drug Trend Report 2000. June 2011. Available at: http://www.express-scripts.com/research/studies/drugtrendreport/2000/2000DrugTrend.pdf. Accessed July 15, 2011.
16. Nease B, Miller S, Frazee SG, et al. Express Scripts Drug Trend Report 2010. April 2011. Available at: http://www.express-scripts.com/research/studies/drugtrendreport/2010/dtrFinal.pdf. Accessed June 23, 2011
17. Department of Health. Extent and causes of international variations in drug usage. A report for the Secretary of State for Health by Professor Sir Mike Richards CBE. July 27, 2010. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_117962. Accessed July 18, 2011.
18. Brookes L. The "Global Challenge" statement from the ISH 2006 meeting, with many clinical trial results. November 17, 2006. Available at: http://www.medscape.org/viewarticle/547752_print. Accessed July 8, 2011.
19. Julius S, Nesbitt SD, Egan BM, et al.; TROPHY study investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354(16):1685-97. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa060838. Accessed July 15, 2011.
20. Williams SA, Michelson EL Cain VA, et al, TROPHY Study Investigators. An evaluation of the effects of an angiotensin receptor blocker on healthrelated quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY). J Clin Hypertens. 2008;10(6):436-42.
21. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358(9294):1682-86.
22. Hughes S. TROPHY in "prehypertension" continues to cause debate. Theheart.org. March 9, 2007. Available at: http://www.theheart.org/article/775197.do. Accessed July 11, 2011.
23. Lüders S, Schrader J, Berger J, et al.; PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26(7):1487-96.
24. Brugts JJ, Yetgin T, Gotto AM, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. Online first 2 July 2009. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714690/?tool=pubmed. Accessed July 15, 2011.
25. Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention. Arch Intern Med. 2010;170(12):1024-31. Available at: http://archinte.ama-assn.org/cgi/content/full/170/12/1024. Accessed July 15, 2011.
26. Ridker PM, Danielson E, Fonseca FAH, et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359(21):2195-207. Published online ahead of print on Nov 9, 2008. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa0807646. Accessed June 23, 2011.
27. Curtiss FR, Fairman KA. Tough questions about the value of statin therapy for primary prevention: did Jupiter miss the moon? J Manag Care Pharm. 2010;16(6):417-23. Available at: http://www.amcp.org/data/jmcp/417-423.pdf.
28. Graf J. Analgesic use in the elderly: the "pain" and simple truth. Arch Intern Med. 2010;170(22):1976-78.
29. California Pain Patients Bill of Rights: California Senate Bill No 402. September 1997. Available at: http://www.chem.arizona.edu/courseweb/081/CHEM4361/reading_pdfs/students/patients_bill_rights.html. Accessed July 7, 2011.
30. Braden JB, Sullivan MD, Ray GT, et al. Trends in long-term opioid therapy for non-cancer pain among persons with a history of depression. Gen Hosp Psychiatry. 2009;31(6):564-70. Available at: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC2774904/?tool=pubmed. Accessed July 7, 2011.
31. Fortuna RJ, Robbins BW, Caiola E, Joynt M, Halterman JS. Prescribing of controlled medications to adolescents and young adults in the United States. Pediatrics. 2010;126(6):1108-16. Available at: http://pediatrics.aappublications. org/content/126/6/1108.long. Accessed July 7, 2011.
32. Cicero TJ, Inciardi JA, Muñoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005;6(10):662-72.
33. Cicero TJ, Surratt H, Inciardi JA, Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf. 2007;16(8):827-40.
34. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15:618-27.
35. Paulozzi LJ, Xi Y. Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiol Drug Saf. 2008;17(10:997-1005.
36. Paulozzi LJ. Drug-induced deaths-United States, 2003-2007. MMWR Surveill Summ. 2011;60 Suppl:60-61. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/su6001a12.htm. Accessed July 11, 2011.
37. U.S. Department of Health & Human Services, Centers for Disease Control and Prevention. Unintentional drug poisoning in the United States. July 2010. Available at: http://www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdf. Accessed July 15, 2011.
38. Goodnough A, Zezima K. Drug is harder to abuse, but users persevere. NY Times. June 15, 2011. Available at: http://www.nytimes.com/2011/06/16/health/16oxy.html. Accessed July 15, 2011.
39. U.S. Food and Drug Administration. FDA acts to reduce harm from opioid drugs. April 19, 2011. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm251830.htm. Accessed July 15, 2011.
40. Mathews AW. So young and so many pills. Wall Street J. December 28, 2010. Available at: http://online.wsj.com/article/SB100014240529702037310 04576046073896475588.html. Accessed July 15, 2010.
41. Cox ER, Halloran DR, Homan SM, Welliver S, Mager DE. Trends in the prevalence of chronic medication use in children: 2002-2005. Pediatrics. 2008;122(5):e1053-61. Available at: http://pediatrics.aappublications.org/content/122/5/e1053.full. Accessed July 7, 2011.
42. Liberman JN, Berger JE, Lewis M. Prevalence of antihypertensive, antidiabetic, and dyslipidemia prescription medication use among children and adolescents. Arch Pediatr Adoles Med. 2009;163(4):357-64. Available at: http://archpedi.ama-assn.org/cgi/reprint/163/4/357. Accessed July 11, 2011.
43. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679-85. Available at: http://archpsyc.amaassn. org/cgi/content/abstract/63/6/679. Accessed July 15, 2011.
44. Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs DC, Ray WA. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6(2):79-83.
45. Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH. First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescens. J Can Acad Child Adolesc Psychiatry. 2010;19(2):124-37. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868560/?tool=pubmed. Accessed July 11, 2011.
46. Lowry F. Antipsychotics may put kids on the fast track to CVD. Medscape. June 20, 2011. http://www.medscape.com/viewarticle/744929_ print. Accessed July 11, 2011.
47. Pediatric Trials Network. New national initiative to rigorously study pediatric dosing safety of prescription medicines. Available at: https://pediatrictrials.org/about-us/ptn-news-papers/new-national-initiative-torigorously-study-pediatric-dosing-safety-of-prescription-medicines. Accessed June 23, 2011.
48. Pediatric Trials Network. Projects. Available at: https://pediatrictrials. org/projects. Accessed June 23, 2011.
49. Organisation for Economic Co-operation and Development. Health at a Glance 2007: OECD Indicators. Paris, France: OECD; 2007.
50. Nolte E, Newbould J, Conklin A. International variation in the usage of medicines: a review of the literature. RAND. 2010. Available at: http://www. rand.org/pubs/technical_reports/TR830.html. Accessed July 20, 2011.
51. Parkin L, Hagberg KW, Jick H. Comprehensive comparison of drug prescribing in the United States and United Kingdom. Pharmacotherapy. 2011;31(7):623-29.
52. Organisation for Economic Co-operation and Development. Pharmaceutical pricing policies in a global market: executive summary. 2008. Available at: http://www.oecd.org/dataoecd/36/2/41303903.pdf. Accessed July 19, 2011.
53. Docteur E. Pharmaceutical pricing policy in a global market.Presentation to: Workshop on Current Pharmaceuticals Challenges, European Health Forum Gastein; October 1, 2008. Available at: http://www.ehfg.org/fileadmin/ehfg/Website/Archiv/2008/Powerpoints/WS2/08_WS2_ Docteur.pdf. Accessed July 19, 2011.
54. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002;324(7342):886-91. Available at: http://www.bmj.com/content/324/7342/886.1.long. Accessed July 19, 2011.
55. Alonso-Coello P, Garcia-Franco AL, Guyatt G, Moynihan R. Drugs for pre-osteoporosis: prevention or disease mongering? BMJ. 2008;336:126-29. Available at: http://www.bmj.com/content/336/7636/126.full.pdf. Accessed July 19, 2011.
56. Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Manag Care Pharm. 1998;4(5):488-92. Available at: http://amcp.org/WorkArea/DownloadAsset.aspx?id=6025.
57. Highlights of prescribing information. Boniva (ibandronate sodium) tablets. Genentech. January 2011. Available at: http://www.gene.com/gene/products/information/boniva/pdf/pi.pdf. Accessed July 20, 2011.
58. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-22. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMoa067312. Accessed July 20, 2011.
59. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356:1995-96. Available at: http://www.nejm.org/doi/full/10.1056/NEJMc076132. Accessed July 20, 2011.
60. Kim SY, Kim MJ, Cadarette SM, Solomon DH. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res Ther. 2010;12(1):R30. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875664/?tool=pubmed. Accessed July 20, 2011.
61. Bhuriya R, Singh M, Molnar J, Arora R, Khosla S. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and metaanalysis. Int J Cardiol. 2010;142(3):213-17.
62. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf. 2009;32(3):219-28.
63. U.S. Food and Drug Administration. FDA drug safety communication: safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. October 13, 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm229009.htm. Accessed July 20, 2011.
64. Dooren JC. FDA issues warning on osteoporosis drug. Wall Street J. Oct 14, 2010:D4. Available at: http://online.wsj.com/article/SB1000142405274870 4763904575550310461425500.html. Accessed July 20, 2011.
65. Guthrie B, McCowan C, Davey P, Simpson CR, Dreishulte T, Barnett K. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ. 2011;342:d3514.
66. Curtiss FR, Fairman KA. Protecting patients from adverse drug events: propoxyphene, PIMs, and drug to avoid in older adults. J Manag Care Pharm. 2011;17(1):60-69. Available at: http://www.amcp.org/data/jmcp/60-69.pdf.
67. Budnitz DS. Agreement between drugs-to-avoid criteria and expert assessments of problematic prescribing - invited commentary. Arch Intern Med. 2009;169(14):1332-34.
68. Reinberg S. Many using free preventive screenings tied to health care reform: Medicare heads say offering the tests free will save money long term, but critics disagree. HealthDay. June 21, 2011. Available at: http://health. usnews.com/health-news/diet-fitness/diabetes/articles/2011/06/20/manyusing-free-preventive-screenings-tied-to-health-care-reform. Accessed July 7, 2011.
69. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med. 2008;358(7):661-63. Available at: http://www.nejm.org/doi/full/10.1056/NEJMp0708558. Accessed July 15. 2011.
70. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation. 2008;118(5):576-85. Available at: http://circ.ahajournals.org/content/118/5/576.long. Accessed July 7, 2011.
71. Järvinen TL, Sievänen H, Kannus P, Jokihaara J, Khan KM. The true cost of pharmacological disease prevention. BMJ. 2011;342:d2175 doi:10.1136/bmj.d2175.
72. Van Staa TP, Leufkens HG, Zhang B, Smeeth L. A comparison of costeffectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example. PLoS Med. 2009;6(12):e1000194. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779340/pdf/pmed.1000194.pdf. Accessed July 7, 2011.
73. Fairman KA, Motheral BR. Do decision-analytic models identify costeffective treatments? A retrospective look at Helicobacter pylori eradication. J Manag Care Pharm. 2003;9(5):430-40. Available at: http://www.amcp.org/data/jmcp/Formulary%20Management-430-440.pdf.
74. Hlatky MA. Expanding the orbit of primary prevention-moving beyond JUPITER. N Engl J Med. 2008;359(21):2280-82. Available at: http://www. nejm.org/doi/full/10.1056/NEJMe0808320. Accessed July 15, 2011.